Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR1 | P30556 | 12/20 | 0.54 |
| ▸ | LTB4R2 | Q9NPC1 | 4/20 | 0.44 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.44 |
| ▸ | GP6 | Q9HCN6 | 1/20 | 0.44 |
| ▸ | FNTA | P49354 | 3/20 | 0.34 |
| ▸ | FNTB | P49356 | 3/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2552 | 1.00 | AGTR1 (0.54) | AGTR1LTB4R2ABCB11GP6FNTA | |
| SCHEMBL7271536 | 0.90 | AGTR1 (0.62) | AGTR1LTB4R2ABCB11GP6MEN1 | |
| SCHEMBL7271546 | 0.90 | AGTR1 (0.62) | AGTR1LTB4R2ABCB11GP6MEN1 | |
| SCHEMBL8487083 | 0.87 | AGTR1 (0.53) | AGTR1LTB4R2ABCB11GP6 | |
| SCHEMBL2874 | 0.86 | AGTR1 (0.52) | AGTR1LTB4R2ABCB11GP6 | |
| SCHEMBL2875 | 0.86 | AGTR1 (0.52) | AGTR1LTB4R2ABCB11GP6 | |
| SCHEMBL389245 | 0.85 | AGTR1 (0.62) | AGTR1LTB4R2ABCB11GP6 | |
| SCHEMBL1322442 | 0.85 | AGTR1 (0.62) | AGTR1LTB4R2ABCB11GP6 | |
| SCHEMBL27898249 | 0.85 | AGTR1 (0.62) | AGTR1LTB4R2ABCB11GP6 | |
| SCHEMBL29846453 | 0.85 | AGTR1 (0.62) | AGTR1LTB4R2ABCB11GP6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5399578-A | Hypotensive; valsartan; high blood pressure and cardiac insufficiency | CIBA-GEIGY CORP (US) | 1995-03-21 | — | — | US | disclosed |